Kiora Pharmaceuticals (NASDAQ:KPRX) is a clinical-stage biotechnology company developing and commercializing products for the treatment of retinal diseases.
KIO-301 is being developed to treat retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with retinal degeneration.
KIO-104 is being developed to treat retinal inflammatory diseases. It is a non-steroidal, immuno-modulatory small-molecule inhibitor of dihydroorotate dehydrogenase.
For more information, please visit www.kiorapharma.com, and follow us on our social media accounts including Twitter and LinkedIn.
